Cargando…

Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?

BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprenger, Thilo, Rothe, Hilka, Jung, Klaus, Christiansen, Hans, Conradi, Lena C, Ghadimi, B Michael, Becker, Heinz, Liersch, Torsten
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864265/
https://www.ncbi.nlm.nih.gov/pubmed/20388220
http://dx.doi.org/10.1186/1477-7819-8-27
_version_ 1782180766522802176
author Sprenger, Thilo
Rothe, Hilka
Jung, Klaus
Christiansen, Hans
Conradi, Lena C
Ghadimi, B Michael
Becker, Heinz
Liersch, Torsten
author_facet Sprenger, Thilo
Rothe, Hilka
Jung, Klaus
Christiansen, Hans
Conradi, Lena C
Ghadimi, B Michael
Becker, Heinz
Liersch, Torsten
author_sort Sprenger, Thilo
collection PubMed
description BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS). RESULTS: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). CONCLUSIONS: Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters.
format Text
id pubmed-2864265
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28642652010-05-05 Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? Sprenger, Thilo Rothe, Hilka Jung, Klaus Christiansen, Hans Conradi, Lena C Ghadimi, B Michael Becker, Heinz Liersch, Torsten World J Surg Oncol Research BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS). RESULTS: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). CONCLUSIONS: Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters. BioMed Central 2010-04-13 /pmc/articles/PMC2864265/ /pubmed/20388220 http://dx.doi.org/10.1186/1477-7819-8-27 Text en Copyright ©2010 Sprenger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sprenger, Thilo
Rothe, Hilka
Jung, Klaus
Christiansen, Hans
Conradi, Lena C
Ghadimi, B Michael
Becker, Heinz
Liersch, Torsten
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title_full Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title_fullStr Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title_full_unstemmed Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title_short Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
title_sort stage ii/iii rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864265/
https://www.ncbi.nlm.nih.gov/pubmed/20388220
http://dx.doi.org/10.1186/1477-7819-8-27
work_keys_str_mv AT sprengerthilo stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT rothehilka stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT jungklaus stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT christiansenhans stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT conradilenac stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT ghadimibmichael stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT beckerheinz stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification
AT lierschtorsten stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification